Summary & Overview
HCPCS J0642: Levoleucovorin (Khapzory) Injection, 0.5 mg
HCPCS Level II code J0642 identifies levoleucovorin (Khapzory) in a 0.5 mg injectable unit. Levoleucovorin is used as an adjunct in oncology care to mitigate toxicity or augment certain chemotherapy regimens; as a HCPCS Level II drug code it matters nationally for drug billing, prior authorization processes, and pharmacy inventory management across outpatient infusion settings. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage context, and practical information relevant to claims submission and billing workflows. The publication covers national benchmarks where available, payer policy themes such as coverage and prior authorization practices, recent policy updates affecting HCPCS drug coding, and the clinical context for levoleucovorin use. Where specific data elements are not provided in the source, the text notes that data are not available in the input. The goal is to give billing managers, revenue cycle leaders, and clinical pharmacists a focused reference for HCPCS Level II code J0642.
Billing Code Overview
HCPCS Level II code J0642 represents an injection of levoleucovorin (Khapzory), 0.5 mg. This entry-level HCPCS code denotes a specific, single-agent parenteral product used in conjunction with certain chemotherapeutic regimens to reduce toxicity or enhance efficacy.
Service Type: Drug administration — injectable antineoplastic adjunct
Typical Site of Service: Hospital outpatient department, physician office, or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving high-dose methotrexate for malignancies such as non-Hodgkin lymphoma, osteosarcoma, or acute lymphoblastic leukemia. Following methotrexate administration, the patient requires rescue therapy with intravenous levoleucovorin (J0642) to reduce toxic effects. The care setting is most commonly an outpatient infusion center or hospital infusion suite where oncology nursing provides scheduled IV bolus or short infusion doses. Workflow: verify prescription and weight-based dosing, confirm timing relative to methotrexate levels, prepare J0642 (0.5 mg units) per pharmacy compounding protocols, document lot number and expiration, administer via peripheral or central IV access, monitor for adverse reactions during and after administration, and record administration in the infusion record and the medication administration record for billing using the J0642 HCPCS code with appropriate modifiers and diagnosis linkage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (default) | Use when no additional modifier is applicable and standard billing applies. |